---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-000738"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:39:44.823478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Esperion prelim Q4 2022 US revenue $14.4-15.1M (+38-40% YoY); CLEAR Outcomes submissions planned 1H 2023

## Summary
- Preliminary Q4 2022 U.S. net product revenue $14.4M-$15.1M; full-year 2022 growth 38%-40% YoY.
- Cash and investment securities ~$167M as of Dec 31, 2022; ~74.6M shares outstanding.
- Plans to submit CLEAR Outcomes data to FDA and EMA in 1H 2023; expects partner milestone payments upon approvals.
- Announces 12-month marketing partnership with RFK Racing to boost brand awareness among 10M+ fans.
- Presenting at J.P. Morgan 41st Annual Healthcare Conference.

## SEC filing metadata
- accession: 0001628280-23-000738
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/0001628280-23-000738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/espr-20230108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-000738
- JSON: https://secwatch.observer/filing/0001628280-23-000738.json
- Plain text: https://secwatch.observer/filing/0001628280-23-000738.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported fourth-quarter 2022 results: revenue $14.4 to $15.1 million.
  - Period: fourth-quarter 2022
  - Revenue: $14.4 to $15.1 million
  - Result: preliminary results
  source text: Preliminary, unaudited fourth-quarter 2022 net U.S. product sales are expected to be between $14.4 to $15.1 million; FY growth between 38% and 40% year over year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828023000738/0001628280-23-000738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.